# Anti-FCER2 [BU38]

Catalogue number: 151430 Sub-type: Primary antibody Images:

### Contributor

Inventor: Institute: University of Birmingham Images:

## **Tool details**

#### **\*FOR RESEARCH USE ONLY**

Name: Anti-FCER2 [BU38]

ols.org Alternate name: Fc Fragment Of IgE Receptor II; Immunoglobulin E-Binding Factor; Lymphocyte IgE Receptor; Fc Epsilon Receptor II; CD23 Antigen; BLAST-2; CLEC4J; IGEBF; FCE2; C-Type Lectin Domain Family 4; Member; Immunoglobulin Epsilon-Chain; CD23

Class: Monoclonal Conjugate: Unconjugated Description: Fc epsilon RII (CD23), a low-affinity IgE receptor, is widely expressed on the surface of a number of cell types. Fc epsilon RII mediates numerous IgE-related immune responses. Both membrane and soluble Fc epsilon RII play important roles in allergic responses. Purpose: Parental cell: **Organism: Tissue:** Model: Gender: Isotype: IgG1 Reactivity: Human Selectivity: Host: Mouse Immunogen: Full length native CD23 of human origin Immunogen UNIPROT ID: Sequence: Growth properties: Production details: Formulation: **Recommended controls:** 

Follicular lymphoma or tonsil (mantle cell lymphomas are negative) **Bacterial resistance:** Selectable markers: Additional notes:

# **Target details**

Target: Fc epsilon RII (FCER2, CD23)

#### **Target alternate names:**

Target background: Fc epsilon RII (CD23), a low-affinity IgE receptor, is widely expressed on the surface of a number of cell types. Fc epsilon RII mediates numerous IgE-related immune responses. Both membrane and soluble Fc epsilon RII play important roles in allergic responses.

#### Molecular weight:

Ic50:

# **Applications**

, vVB Cancer Tools.org **Application:** FACS ; IHC ; IF ; IP ; WB **Application notes:** 

# Handling

Format: Liquid Concentration: 0.9-1.1 mg/ml Passage number: Growth medium: **Temperature:** Atmosphere: Volume: Storage medium: Storage buffer: PBS with 0.02% azide Storage conditions: -15° C to -25° C Shipping conditions: Shipping at 4° C

# **Related tools**

Related tools:

# References

**References:** Bortolotti et al. 2016. Toxins (Basel). 8(6):. PMID: 27338475. ; High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin. ; Flavell et al. 2006. Br J Haematol. 134(2):157-70. PMID: 16771848. ; The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma. ; Behr et al. 1995. J Exp Med. 182(5):1191-9. PMID: 7595190. ; Engaging CD19 or target of an antiproliferative antibody 1 on human B lymphocytes induces binding of B cells to the interfollicular stroma of human tonsils via integrin alpha 4/beta 1 and fibronectin. ; Schlossman SF. et al. 1995. Leucocyte Typing V. Oxford University Press ; Callard et al. 1992. J Immunol. 148(10):2983-7. PMID: 1374445. ; CD19 regulation of human B cell responses. B cell proliferation and antibody secretion are inhibited or enhanced by ligation of the CD19 surface glycoprotein depending on the stimulating signal used.

Cancer Tools.org